Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yong-Chen Lu"'
Autor:
Benjamin J. Lieblong, Erich A. Peterson, Toshiyuki Sasagawa, Teresa Evans, Sumit K. Shah, Donald J. Johann, Yong-Chen Lu, Hannah N. Coleman, Takeo Shibata, Horace J. Spencer, Charles M. Quick, Owen W. Stephens, Mayumi Nakagawa
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Advances in high-throughput sequencing have revolutionized the manner with which we can study T cell responses. We describe a woman who received a human papillomavirus (HPV) therapeutic vaccine called PepCan, and experienced complete resolution of he
Autor:
Jared J. Gartner, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg, Frank J. Lowery, Todd D. Prickett, Zhili Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundRecognition of neoantigens by T cells plays a major role in cancer immunotherapy. Identification of neoantigen-specific T-cell receptors (TCRs) has become a critical research tool for studying T cell-mediated responses after immunotherapy.
Autor:
Anna Pasetto, Yong-Chen Lu
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
T cells have been known to be the driving force for immune response and cancer immunotherapy. Recent advances on single-cell sequencing techniques have empowered scientists to discover new biology at the single-cell level. Here, we review the single-
Autor:
Paul F. Robbins, Yong-Chen Lu, Xin Yao, Steven A. Feldman, Yong F. Li, Steven A. Rosenberg, Linda L. Parker, Pierre van der Bruggen, Hui Xu, Mona El-Gamil, Mary A. Black
Long-term tumor regressions have been observed in patients following the adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) or genetically-modified T cells expressing MHC class I-restricted T cell receptors (TCRs), but clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ec4a33f0b4a9e9e186f27271657def3
https://europepmc.org/articles/PMC4947411/
https://europepmc.org/articles/PMC4947411/
Autor:
Zhili Zheng, Udai S. Kammula, Paul F. Robbins, Steven A. Rosenberg, Yong-Chen Lu, Christopher A. Klebanoff, Stephanie L. Goff, James Chih-Hsin Yang, Richard M. Sherry, Linda L. Parker, Xin Yao, Steven A. Feldman, Christian S. Hinrichs, Pierre van der Bruggen, Tangying Lu
Publikováno v:
Cancer Research. 76:CT003-CT003
Background: Adoptive transfer of genetically-modified T cells is being explored as a salvage treatment for patients with selected metastatic cancers. Most of the current strategies utilize MHC class I-restricted T cell receptor (TCR) or chimeric anti
Autor:
Christian S. Hinrichs, James Chih-Hsin Yang, Xin Yao, Yong-Chen Lu, Zhili Zheng, Udai S. Kammula, Linda L. Parker, Tangying Lu, Steven A. Rosenberg, Richard M. Sherry, Christopher A. Klebanoff, Stephanie L. Goff, Paul F. Robbins, Pierre van der Bruggen
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Adoptive transfer of genetically-modified T cells is being explored as a salvage treatment for patients with selected metastatic cancers. Most of the current strategies utilize MHC class I-restricted T cell receptor (TCR) or chimeri